Insider Selling: Haemonetics Co. (NYSE:HAE) EVP Sells $77,942.04 in Stock

Haemonetics Co. (NYSE:HAE) EVP Josep Llorens sold 822 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $94.82, for a total transaction of $77,942.04. Following the sale, the executive vice president now directly owns 16,350 shares in the company, valued at $1,550,307. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Josep Llorens also recently made the following trade(s):

• On Monday, May 20th, Josep Llorens sold 987 shares of Haemonetics stock. The stock was sold at an average price of $95.08, for a total value of $93,843.96.

Haemonetics Price Performance

NYSE:HAE opened at $88.64 on Friday. Haemonetics Co. has a one year low of $70.74 and a one year high of $97.97. The stock has a market cap of $4.51 billion, a PE ratio of 38.71, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.50 and a current ratio of 2.56. The stock has a 50 day moving average price of $87.51 and a 200 day moving average price of $83.46.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The business had revenue of $343.00 million during the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The company’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same period last year, the company earned $0.77 EPS. Equities research analysts expect that Haemonetics Co. will post 4.6 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on HAE shares. Needham & Company LLC reissued a “hold” rating on shares of Haemonetics in a research note on Friday, May 10th. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. JMP Securities lifted their price target on Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 10th. Barrington Research increased their price objective on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Finally, StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $108.67.

Hedge Funds Weigh In On Haemonetics

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Haemonetics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after purchasing an additional 27,146 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Haemonetics during the fourth quarter worth about $888,000. Kingdon Capital Management L.L.C. acquired a new stake in shares of Haemonetics during the third quarter valued at about $9,952,000. Lazard Asset Management LLC raised its stake in shares of Haemonetics by 114.2% in the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 20,550 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Haemonetics by 1.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock worth $4,753,000 after acquiring an additional 586 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.